glp 1 agonist and dpp 4 inhibitor Design principles of long-acting DPP-4 inhibitors The Role of DPP-4

glp 1 agonist and dpp 4 inhibitor Design principles of long-acting DPP-4 inhibitors The Role of DPP-4

The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect

3 Although no studies have prospectively stratified patients by baseline A1C in evaluation of the A1C-lowering efficacy of a DPP-4 inhibitor or SGLT2 inhibitor, post-hoc subgroup analyses have shown that the efficacy of SGLT2 inhibitors is greater than that of DPP-4 inhibitors among patients with higher baseline A1C (≥ 8-8.5%), while patients with baseline A1C at the lower end of the spectrum ( 30 mL/min and clinical CV disease according to Diabetes Canada

The risk may be particularly high in patients with underlying heart failure or kidney disease